T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Status: | Suspended |
---|---|
Conditions: | Breast Cancer, Ovarian Cancer, Cancer, Cancer, Cancer, Cancer, Brain Cancer, Blood Cancer, Lymphoma, Hematology, Leukemia |
Therapuetic Areas: | Hematology, Oncology |
Healthy: | No |
Age Range: | 18 - 120 |
Updated: | 11/11/2018 |
Start Date: | December 2006 |
End Date: | December 2022 |
Regulatory T Cells at Engraftment as Predictors of Acute Graft-Versus-Host Disease Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
doctors predict whether patients undergoing donor stem cell transplant will develop acute
graft-versus-host disease.
PURPOSE: This clinical trial is studying T cells to see how well they help in predicting
acute graft-versus-host disease in patients undergoing donor stem cell transplant.
doctors predict whether patients undergoing donor stem cell transplant will develop acute
graft-versus-host disease.
PURPOSE: This clinical trial is studying T cells to see how well they help in predicting
acute graft-versus-host disease in patients undergoing donor stem cell transplant.
OBJECTIVES:
- To determine the association between regulatory T-lymphocyte (Treg) subsets present at
engraftment and at day 28 with the incidence of acute graft-versus-host-disease (aGVHD)
in patients undergoing allogeneic stem cell transplantation.
- To identify gut-homing and skin-homing Treg subsets and determine their role during
engraftment and at day 28 as a predictor of gut and skin aGVHD, respectively.
OUTLINE: Patients undergo blood sample collection at the time of neutrophil engraftment prior
to stem cell transplant (SCT) and post-SCT on days 7, 14, 21, and 28 days after allogeneic
stem cell transplantation. Blood samples are analyzed for T-cell subsets and for the
percentage of regulatory T-lymphocyte (Treg) or other T-cell subsets expressing specific
homing receptors for the gut or skin via flow cytometry.
Patients' medical records are also reviewed periodically.
- To determine the association between regulatory T-lymphocyte (Treg) subsets present at
engraftment and at day 28 with the incidence of acute graft-versus-host-disease (aGVHD)
in patients undergoing allogeneic stem cell transplantation.
- To identify gut-homing and skin-homing Treg subsets and determine their role during
engraftment and at day 28 as a predictor of gut and skin aGVHD, respectively.
OUTLINE: Patients undergo blood sample collection at the time of neutrophil engraftment prior
to stem cell transplant (SCT) and post-SCT on days 7, 14, 21, and 28 days after allogeneic
stem cell transplantation. Blood samples are analyzed for T-cell subsets and for the
percentage of regulatory T-lymphocyte (Treg) or other T-cell subsets expressing specific
homing receptors for the gut or skin via flow cytometry.
Patients' medical records are also reviewed periodically.
Inclusion criteria:
- Patients undergoing allogeneic SCT
- Age >= 18 years
Exclusion criteria:
- Inability to give informed consent
- Patients who have not received an allogeneic SCT
- Any condition which, in the opinion of the investigator, might interfere with study
objective
- Any reason which, in the opinion of the investigator, adds additional risk to the
patient
We found this trial at
1
site
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
Click here to add this to my saved trials